Bridgefront Capital LLC Acquires New Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Bridgefront Capital LLC purchased a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 19,011 shares of the biotechnology company's stock, valued at approximately $252,000. Bridgefront Capital LLC owned approximately 0.06% of AnaptysBio at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of AnaptysBio by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 644 shares in the last quarter. Virtus ETF Advisers LLC lifted its holdings in AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 936 shares during the last quarter. Rhumbline Advisers raised its holdings in AnaptysBio by 3.8% in the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company's stock valued at $398,000 after acquiring an additional 1,111 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 1,531 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in shares of AnaptysBio in the 4th quarter valued at $40,000.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB traded down $0.90 during trading hours on Wednesday, hitting $19.62. The company's stock had a trading volume of 165,919 shares, compared to its average volume of 596,218. The stock has a market cap of $576.44 million, a price-to-earnings ratio of -3.23 and a beta of -0.20. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $41.31. The business has a 50-day simple moving average of $18.78 and a 200-day simple moving average of $18.43.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.30) by $0.02. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $27.77 million during the quarter, compared to analyst estimates of $15.27 million. On average, equities research analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has approved a share buyback plan on Monday, March 24th that allows the company to repurchase $75.00 million in shares. This repurchase authorization allows the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their price objective on AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Johnson Rice reissued a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Guggenheim upped their price target on AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. HC Wainwright reaffirmed a "neutral" rating and set a $22.00 price target on shares of AnaptysBio in a research note on Tuesday, March 4th. Finally, Wolfe Research started coverage on AnaptysBio in a research note on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, AnaptysBio presently has a consensus rating of "Moderate Buy" and an average target price of $35.88.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.